A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and anti-tumor activity of PF-07220060 as a Single Agent and as Part of Combination Therapy in Participants with Advanced Solid tumors (WIRB)

Primary Outcome Measures  :

1. Number of participants with dose limiting toxicities in the Dose Escalation Portion [ Time Frame: Baseline up to day 28 of Cycle 1. ]
   
2. Incidence of clinically significant AEs [ Time Frame: Weekly during Cycle 1 and 2 and then every 28 days through study completion, up to approximately 24 months; Each cycle is 28 days ]Adverse Events
   
3. Incidence of clinically significant laboratory assessments [ Time Frame: Weekly during Cycle 1 and 2 (each cycle is 28 days) and then every 28 days through study completion, up to approximately 24 months ]safety laboratory abnormalities
   
4. Incidence of clinically significant abnormal vital and ECG parameters [ Time Frame: Day 1, Day 8, Day 15 of Cycle 1 and starting from Cycle 2, and then every 28 days through study completion, up to approximately 24 months (Each cycle is 28 days) ]vital signs and heart rate corrected QT interval

Inclusion Criteria

• Disease Characteristics - Breast Cancer (Part 1A, Part 1B and Part 1C)
• Refractory Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) breast cancer (2L + with prior CDK 4/6) locally advance or metastatic breast cancer. Participants should have received at least 1 line of SOC, including CDK4/6 inhibitor therapy, or at least 1 line of anti-endocrine therapy in countries without CDK4/6 inhibitor approval or reimbursement, for advanced or metastatic disease
• Part 1A only: Refractory HR-positive (HR+), Human Epidermal Growth Factor Receptor 2 Positive (HER2+) breast cancer
• Evaluable lesion (including skin or bone lesion only)
• Disease Characteristics - Part 1A: Tumors other than BC
• Participants with advanced or metastatic disease
• Participants with histological or cytological diagnosis of adenocarcinoma of NSCLC, prostate, CRC, liposarcoma, or tumors with previously confirmed CDK4 or CCND1 amplification according to local standard tests, that is resistant to at least 2 lines of standard systemic therapy for advanced or recurrent disease or for which no standard therapy is available
• Participants must not be eligible to undergo therapy with curative intent (surgery or radiation therapy with or without chemotherapy

General Inclusion Criteria

• All participants must be refractory to or intolerant of existing therapies known to provide clinical benefit for their condition.
• Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1
• Adequate renal, liver, and bone marrow function

Exclusion Criteria:

• Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases carcinomatous meningitis, or leptomeningeal disease
• Other active malignancy within 3 years prior to randomization, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ
• Major surgery or radiation within 4 weeks prior to study intervention
• Last anti-cancer treatment within 2 weeks prior to study intervention
• Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry
• Pregnant or breastfeeding female participant
• Active inflammatory gastrointestinal (GI) disease, known diverticular disease or previous gastric resection or lap band surgery including impairment of gastrointestinal function or GI disease